Instituut voor Neuropathische Pijn
English articles Research & Development Melatonin: protective in chemotherapy for neuropathy?
| Melatonin: protective in chemotherapy for neuropathy? |
|
Melatonin demonstrated neuroprotective effects in a variety of animal studies and has been suggested to decrease adverse reactions of chemotherapy including neuropathy. In a pilot trial melatonin, 21 mg before sleep, given during taxane chemotherapy for breast cancer, decreased the incidence and severity of neuropathy.
The neuroprotective properties from melatonin are becoming interesting. [1] Twenty two patients beginning chemotherapy for breast cancer with paclitaxel, or docetaxel were enrolled. Patients received melatonin 21 mg daily at bedtime. Incidence and severity of neuropathy were assessed using neurological examinations and a quality of life scale. The results were: Neuropathy was seen in 45% ( n = 10) of patients, 23% (n = 6) grade 1 and 22% (n = 5) Grade 2 neuropathy. No grade 3 neuropathies were reported. The majority (55%) of all patients reported no neuropathy. Compliance with melatonin (.60% of dose) was seen in most patients (86%) No patient reported daytime sedation. This incidence is lower than normally seen, but than of cause this was an uncontrolled open trial. Source: Melatonin, a Promising Role in Taxane-Related NeuropathyAuthors: Z. Nahleh, J. Pruemer, J. Lafollette and S. SweanyPublication Date: 28 Apr 2010; Clinical Medicine Insights: Oncology 2010:4 35-41 Jan M. Keppel Hesselink, MD, PhD, may 2010.
Referenties[1]: Belforte NA, Moreno MC, de Zavalía N, Sande PH, Chianelli MS, Keller Sarmiento MI, Rosenstein RE. | Melatonin: a novel neuroprotectant for the treatment of glaucoma. | J Pineal Res. | 2010 May;48(4):353-64. Epub 2010 Mar 16. |